BTI Core Capabilities

Modality Development

The Modality Development division is a cross-functional team dedicated to discovering, developing, and engineering assets; and optimising the production system and scale-up processes across various therapeutic modalities. It encompasses assets such as monoclonal antibodies (mAbs) and stem cells for regenerative medicine, and new modalities such as multi-specific mAbs and antibody-drug conjugates, immune cell therapies and mRNA.

Bioprocess Technologies Development

The Bioprocess Technologies Development division is a multidisciplinary team leading the development of advanced biomanufacturing processes in cell culture bioreactor scale-up and purification of various therapeutic modalities, to drive cost reduction, efficiency, scalability, quality and automation. Through efficient production methods such as continuous and intensified biomanufacturing, it enables translational research for scale-up, adoption and value creation.

Formulation & Deliveries for Genes

Formulation & Deliveries for Genes Division is dedicated to developing innovative delivery strategies for cell and gene therapies. Its focus includes the design and optimisation of novel delivery vehicles to enable the safe, efficient, and cell-type-specific delivery of RNA and other genetic materials. By advancing both formulation science and targeted delivery technologies, it aims to overcome key translational barriers and support next-generation genetic medicines.

Analytical Science and Technology

Analytical Science and Technology is a cross-cutting division leading the characterisation of different biotherapeutic modalities and associated biomanufacturing processes, to ensure the production of safe and effective drugs. To accelerate biotherapeutics development, it has further established AI and mechanistic models for rational, knowledge-driven media design, with the longer-term goal of enabling real-time monitoring and adaptive process control.